These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 39218681)
1. [Cefiderocol: a first and novel class of siderophore cephalosporin for Carbapenem-resistant Gram-negative infection]. Yamano Y; Morita I; Ariyasu M Nihon Yakurigaku Zasshi; 2024; 159(5):331-340. PubMed ID: 39218681 [TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
4. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety. Lee YR; Yeo S Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154 [TBL] [Abstract][Full Text] [Related]
11. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE). Chatterjee S; Chakraborty DS; Choudhury S; Lahiry S Curr Drug Res Rev; 2022; 14(1):20-23. PubMed ID: 34872487 [TBL] [Abstract][Full Text] [Related]
12. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence. Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. Jorda A; Zeitlinger M Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355 [No Abstract] [Full Text] [Related]
15. Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria. Silva JT; López-Medrano F Rev Esp Quimioter; 2021 Sep; 34 Suppl 1(Suppl1):41-43. PubMed ID: 34598424 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795 [TBL] [Abstract][Full Text] [Related]
17. Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy. Bassetti M; Monti G; Henriksen AS; Longshaw C Antimicrob Resist Infect Control; 2024 Aug; 13(1):91. PubMed ID: 39183351 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of the newly approved antimicrobial agent Cefiderocol against Carbapenem resistant Gram negative clinical isolates. Khanchandani H; Chaudhury M; Rao MS; Ramakrishna N; Venkataramana B; Chaudhury A Indian J Med Microbiol; 2024; 48():100556. PubMed ID: 38447857 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]